Scarica l'app Stockscreener
3.86
9.18%
-0.39
Dopo l'orario di chiusura:
3.86
Precedente Chiudi:
$4.25
Aprire:
$4.39
Volume 24 ore:
332.42K
Relative Volume:
0.94
Capitalizzazione di mercato:
$190.16M
Reddito:
$84.82M
Utile/perdita netta:
$-21.43M
Rapporto P/E:
-7.8776
EPS:
-0.49
Flusso di cassa netto:
$-27.23M
1 W Prestazione:
-8.10%
1M Prestazione:
-14.98%
6M Prestazione:
-75.40%
1 anno Prestazione:
-77.61%
Intervallo 1D:
$3.85
$4.46
Intervallo di 1 settimana:
$3.85
$4.60
Portata 52W:
$3.84
$17.47
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Nome
Y Mabs Therapeutics Inc
Settore
Industria
Telefono
646-885-8505
Indirizzo
202 CARNEGIE CENTER, PRINCETON, NY
Confronta YMAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
3.86 | 190.16M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-11-18 | Iniziato | Oppenheimer | Outperform |
| 2024-08-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-28 | Iniziato | Truist | Buy |
| 2023-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-04-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-27 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-12-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-10-31 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-10-31 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-03 | Ripresa | Guggenheim | Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-11-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-23 | Ripresa | Cowen | Outperform |
| 2021-03-22 | Ripresa | JP Morgan | Overweight |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2020-05-01 | Iniziato | Janney | Buy |
| 2020-04-29 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Iniziato | Wedbush | Outperform |
| 2019-04-01 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-10-16 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Cancer Treatment Pioneer Y-mAbs Announces Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - The Manila Times
Y-mAbs Therapeutics, Inc. Scheduled to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1% - Defense World
Legal & General Group Plc Decreases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline - Yahoo Finance
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price - simplywall.st
Y-mAbs Therapeutics (YMAB) Showcases CD38-SADA Data at AACR 2025 - GuruFocus
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Y-mAbs Therapeutics Presents Preclinical Data on CD38-SADA at 2025 AACR Annual Meeting - Nasdaq
Revolutionary Cancer Treatment: Y-mAbs CD38-SADA Therapy Achieves 20X Faster Clearance Rate in Latest Trial - Stock Titan
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $6.44 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Q1 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst - Defense World
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment - Investing.com
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment By Investing.com - Investing.com India
Y-mAbs Therapeutics (YMAB) Begins Phase 1 Trial for Non-Hodgkin - GuruFocus
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - The Manila Times
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform - TipRanks
Y-mAbs Therapeutics Initiates Phase 1 Trial of CD38-SADA Pre-targeted Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma - Nasdaq
Groundbreaking Radioimmunotherapy: Y-mAbs Launches First-in-Human Trial for Advanced Lymphoma Treatment - Stock Titan
When the Price of (YMAB) Talks, People Listen - news.stocktradersdaily.com
Y-mAbs (YMAB) Faces Downgrade as Market Potential Wanes - GuruFocus
Y-mAbs drops as Bank of America downgrades on headwinds to Danyelza - MSN
ITeos Therapeutics Inc (ITOS) Stock: From Low to High in 52 Weeks - investchronicle.com
Y-Mabs Therapeutics Inc Inc. (YMAB) Price Performance: The Role of Supply and Demand - investchronicle.com
Y-Mabs Therapeutics Inc (YMAB) stock: A year of ups and downs - uspostnews.com
Ratio Review: Analyzing Y-Mabs Therapeutics Inc (YMAB)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Bank of America to “Underperform” - Defense World
Y-mAbs stock down as Bank of America downgrades (YMAB:NASDAQ) - Seeking Alpha
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World
Vanguard Group Inc. Trims Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Wellington Management Group LLP Sells 3,451 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter
KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha
Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com
YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Refractory Metastatic Melanoma Clinical and Non-Clinical - openPR.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World
(YMAB) Long Term Investment Analysis - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views - Benzinga
Y Mabs Therapeutics Inc Azioni (YMAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):